fluorouracil has been researched along with Cardiac Toxicity in 54 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was aimed to investigate the protective effects of resveratrol (Res) on 5-FU-induced cardiotoxicity and to explore its potential mechanisms." | 8.31 | Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis. ( Li, D; Song, C; Zhang, J; Zhao, X, 2023) |
| " This study thus aimed at exploring the cardioprotective potentials of naringin (NRG) against 5-FU-induced cardiotoxicity in rats." | 8.31 | Naringin ameliorates 5-fluorouracil induced cardiotoxicity: An insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters. ( Famurewa, AC; Gui, Y; Olatunji, OJ, 2023) |
| "5-Fluorouracil (5-FU)-associated cardiotoxicity has been ranked as the second most common cause of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines." | 8.12 | Cardioprotective effect of silymarin nanoemulsion on 5-fluorouracil-induced cardiotoxicity in rats. ( Ebrahimpour, A; Golchoobian, R; Kazemi, S; Mansoori, R; Moghadamnia, AA; Safarpour, S; Shirafkan, F, 2022) |
| "5-fluorouracil (5-FU) is a widely used chemotherapeutic agent but cardiotoxicity challenges its clinical usefulness." | 8.12 | Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. ( Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM, 2022) |
| "The current study showed that 5FU succeeded in inducing cardiotoxicity, manifested by significantly elevated levels of cardiac enzymes, tissue malondialdehyde (MDA), interleukin 6 (IL-6), signal transducer and activator of transcription 4 (STAT4), and caspase-3." | 8.12 | The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity. ( Abdelzaher, WY; Bayoumi, AMA; El-Tahawy, NFG; Refaie, MMM; Shehata, S, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 8.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 8.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| "The current research was undertaken to design stealth liposomes of 5-Fluorouracil for reducing its cardiotoxicity and prolong the half-life by developing long-circulating liposomes." | 8.12 | Development, evaluation and biodistribution of stealth liposomes of 5-fluorouracil for effective treatment of breast cancer. ( Katharotiya, D; Katharotiya, K; Kulkarni, D; Panzade, P; Patel, R; Shelke, S; Shinde, G, 2022) |
| "To determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran." | 8.12 | EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS. ( Abadi, H; Amirmoghaddami, H; Karamitanha, F; Moghaddam, Z; Rostami, M; Zeraatchi, A, 2022) |
| "5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used in treating solid tumors, and the 5-FU-induced cardiotoxicity is the second cause of cardiotoxicity induced by chemotherapeutic drugs." | 8.12 | The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats. ( Barary, M; Hosseini, M; Hosseinzadeh, R; Kazemi, S; Liang, JJ; Mansoori, R; Moghadamnia, AA; Sio, TT, 2022) |
| "Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity." | 8.12 | Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ( Ålgars, A; Bärlund, M; Flygare, P; Frödin, JE; Glimelius, B; Hagman, H; Halonen, P; Heervä, E; Kallio, R; Kinos, S; Kwakman, JJM; Liposits, G; McDermott, R; O'Reilly, M; Osterlund, P; Pfeiffer, P; Punt, CJA; Ristamäki, R; Röckert, R; Salminen, T; Shah, CH; Sorbye, H; Soveri, LM; Teske, AJ; van Werkhoven, E, 2022) |
| "5-Fluorouracil (5-FU) is used in the treatment of different solid tumors; however, its use is associated with rare, but serious cardiotoxicity." | 7.96 | Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. ( El-Abhar, HS; Muhammad, RN; Sallam, N, 2020) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 7.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 7.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 7.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 7.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm." | 7.85 | Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity. ( Agac, MT; Akdemir, R; Akyüz, AR; Aykan, AÇ; Boyacı, F; Celik, S; Cengiz, E; Erkan, H; Gökdeniz, T; Gül, İ; Kul, S; Turan, T, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 7.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 6.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| " Currently, there is insufficient evidence to recommend an optimal approach for safe and effective alternative treatment for patients who experience 5-fluorouracil-induced cardiac adverse events." | 6.53 | Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016) |
| "Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5-FU (100 mg/kg)." | 5.72 | Protective Effect of Kaempferol and Its Nanoparticles on 5-Fluorouracil-Induced Cardiotoxicity in Rats. ( Ebrahimpour, A; Hosseini, M; Kazemi, S; Madani, F; Moghadamnia, AA; Pirzadeh, M; Safarpour, S; Shirafkan, F, 2022) |
| " Screening patients for dihydropyrimidine dehydrogenase deficiency prior to 5-FU administration may facilitate an individualized strategy for optimal dosing and safety." | 5.56 | 5-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 5.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 5.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| " We tested the hypotheses that adjuvant treatment for early breast cancer with the anthracycline epirubicin is dose dependently associated with increased ECV fraction and total ECV, as well as reduced total myocardial cellular volume, and that these changes could be prevented by concomitant angiotensin or beta-adrenergic blockade." | 5.27 | Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. ( Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2018) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent that can cause cardiotoxicity manifesting, among others, as chest pain." | 5.22 | 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations. ( Boulmpou, A; Charalampidis, P; Giannakoulas, G; Papadopoulos, CE; Teperikidis, E; Tsavousoglou, C; Vassilikos, V, 2022) |
| "5-fluorouracil (5-FU) is one of the most common causes of cardiotoxicity associated with chemotherapy." | 5.12 | 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death. ( Asnani, A; Lane, S; More, LA, 2021) |
| "Cancer patients experienced an increased risk of cardiotoxicity during fluoropyrimidine-based chemotherapy (5-fluorouracil or capecitabine)." | 5.12 | Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2021) |
| " In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described." | 4.98 | [Management of cardiovascular complications secondary to medical treatment of cancer]. ( Banke, A; Fosbøl, EL; Nielsen, D; Nielsen, KM; Overgaard, U; Polk, A; Schou, M; Vaage-Nielsen, M; Videbæk, L, 2018) |
| "The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer." | 4.95 | Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy. ( Abdulganieva, DI; Aliakberova, GI; Gylmanov, AA; Parve, S, 2017) |
| " The present study was aimed to investigate the protective effects of resveratrol (Res) on 5-FU-induced cardiotoxicity and to explore its potential mechanisms." | 4.31 | Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis. ( Li, D; Song, C; Zhang, J; Zhao, X, 2023) |
| " This study thus aimed at exploring the cardioprotective potentials of naringin (NRG) against 5-FU-induced cardiotoxicity in rats." | 4.31 | Naringin ameliorates 5-fluorouracil induced cardiotoxicity: An insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters. ( Famurewa, AC; Gui, Y; Olatunji, OJ, 2023) |
| "The current study showed that 5FU succeeded in inducing cardiotoxicity, manifested by significantly elevated levels of cardiac enzymes, tissue malondialdehyde (MDA), interleukin 6 (IL-6), signal transducer and activator of transcription 4 (STAT4), and caspase-3." | 4.12 | The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity. ( Abdelzaher, WY; Bayoumi, AMA; El-Tahawy, NFG; Refaie, MMM; Shehata, S, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 4.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "5-Fluorouracil (5-FU)-associated cardiotoxicity has been ranked as the second most common cause of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines." | 4.12 | Cardioprotective effect of silymarin nanoemulsion on 5-fluorouracil-induced cardiotoxicity in rats. ( Ebrahimpour, A; Golchoobian, R; Kazemi, S; Mansoori, R; Moghadamnia, AA; Safarpour, S; Shirafkan, F, 2022) |
| "5-fluorouracil (5-FU) is a widely used chemotherapeutic agent but cardiotoxicity challenges its clinical usefulness." | 4.12 | Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. ( Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM, 2022) |
| "5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used in treating solid tumors, and the 5-FU-induced cardiotoxicity is the second cause of cardiotoxicity induced by chemotherapeutic drugs." | 4.12 | The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats. ( Barary, M; Hosseini, M; Hosseinzadeh, R; Kazemi, S; Liang, JJ; Mansoori, R; Moghadamnia, AA; Sio, TT, 2022) |
| "Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity." | 4.12 | Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ( Ålgars, A; Bärlund, M; Flygare, P; Frödin, JE; Glimelius, B; Hagman, H; Halonen, P; Heervä, E; Kallio, R; Kinos, S; Kwakman, JJM; Liposits, G; McDermott, R; O'Reilly, M; Osterlund, P; Pfeiffer, P; Punt, CJA; Ristamäki, R; Röckert, R; Salminen, T; Shah, CH; Sorbye, H; Soveri, LM; Teske, AJ; van Werkhoven, E, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 4.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| "To determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran." | 4.12 | EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS. ( Abadi, H; Amirmoghaddami, H; Karamitanha, F; Moghaddam, Z; Rostami, M; Zeraatchi, A, 2022) |
| "The current research was undertaken to design stealth liposomes of 5-Fluorouracil for reducing its cardiotoxicity and prolong the half-life by developing long-circulating liposomes." | 4.12 | Development, evaluation and biodistribution of stealth liposomes of 5-fluorouracil for effective treatment of breast cancer. ( Katharotiya, D; Katharotiya, K; Kulkarni, D; Panzade, P; Patel, R; Shelke, S; Shinde, G, 2022) |
| "To evaluate the changes in left ventricular myocardial function in patients with colorectal cancer undergoing chemotherapy with mFOLFOX6 (oxaliplatin + 5-fluorouracil + calcium folinate) using three-dimensional speckle-tracking echocardiography (3D-STE)." | 4.02 | Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer. ( Dong, S; Feng, J; Guo, X; Huang, L; Liu, K; Lu, G; Qin, W; Wang, Z; Zhai, Z; Zhang, C, 2021) |
| "5-Fluorouracil (5-FU) is used in the treatment of different solid tumors; however, its use is associated with rare, but serious cardiotoxicity." | 3.96 | Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. ( El-Abhar, HS; Muhammad, RN; Sallam, N, 2020) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 3.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 3.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 3.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 3.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 3.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm." | 3.85 | Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity. ( Agac, MT; Akdemir, R; Akyüz, AR; Aykan, AÇ; Boyacı, F; Celik, S; Cengiz, E; Erkan, H; Gökdeniz, T; Gül, İ; Kul, S; Turan, T, 2017) |
| " The present study was aimed to assess cardiotoxicity of DLBS1425, compared to the mainstay regimen for breast cancer, 5-fluorouracil:doxorubicin:cyclophosphamide (FAC, given at 500/50/500 mg/m(2))." | 3.81 | Cardiovascular effects of Phaleria macrocarpa extracts combined with mainstay FAC regimen for breast cancer. ( Anggadiredja, K; Tjandrawinata, RR, 2015) |
| "Cardiotoxicity is a side effect of trastuzumab." | 2.84 | Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II ( Aalders, K; Bartlett, JMS; Biganzoli, L; Bogaerts, J; Cameron, D; De Valk, B; Khaled, H; Marreaud, S; Tryfonidis, K; Vermorken, J; Welnicka-Jaskiewicz, M, 2017) |
| " Toxicities are described per treatment arm according to the Common Toxicity Criteria for Adverse Events version 4." | 2.82 | Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. ( Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E, 2016) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 2.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| "Many trials of anticancer agents have been conducted, excluding patients with heart diseases." | 2.66 | Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. ( Hiraide, M; Shiga, T, 2020) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| "Each anticancer regimen is associated with distinct modes of heart damage, both symptomatic and asymptomatic." | 2.53 | Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. ( Cadeddu, C; Deidda, M; Demurtas, L; Madeddu, C; Mercuro, G; Piras, A; Piscopo, G; Puzzoni, M; Scartozzi, M, 2016) |
| " Currently, there is insufficient evidence to recommend an optimal approach for safe and effective alternative treatment for patients who experience 5-fluorouracil-induced cardiac adverse events." | 2.53 | Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016) |
| "Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5-FU (100 mg/kg)." | 1.72 | Protective Effect of Kaempferol and Its Nanoparticles on 5-Fluorouracil-Induced Cardiotoxicity in Rats. ( Ebrahimpour, A; Hosseini, M; Kazemi, S; Madani, F; Moghadamnia, AA; Pirzadeh, M; Safarpour, S; Shirafkan, F, 2022) |
| "Cardiotoxicity is a severe side effect for colorectal cancer (CRC) patients undergoing fluoropyrimidine-based chemotherapy." | 1.72 | Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2022) |
| " Screening patients for dihydropyrimidine dehydrogenase deficiency prior to 5-FU administration may facilitate an individualized strategy for optimal dosing and safety." | 1.56 | 5-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020) |
| "Of raltitrexed-treated patients, 13 (5%) experienced CV toxicities and 1 (< 0." | 1.51 | Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. ( Braconi, C; Chau, I; Cunningham, D; Forster, M; Gerlinger, M; Kalaitzaki, E; Khan, K; Rane, JK; Rao, S; Starling, N; Valeri, N; Watkins, D, 2019) |
| " The current use of FPDs includes multiple dosing regimens, oral or intravenous delivery, and administration with additional cardiotoxic therapies." | 1.51 | Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. ( Brell, JM; Carver, JR; Denlinger, CS; Dimond, EP; Kircher, SM; Ky, B; O'Neill, A; Upshaw, JN; Wagner, LI, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 1.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 1.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (51.85) | 24.3611 |
| 2020's | 26 (48.15) | 2.80 |
| Authors | Studies |
|---|---|
| Meter, M | 1 |
| Gavran, I | 1 |
| Bajo, D | 1 |
| Duplancic, D | 1 |
| Li, C | 2 |
| Chen, L | 2 |
| Chou, C | 2 |
| Ngorsuraches, S | 2 |
| Qian, J | 2 |
| Refaie, MMM | 2 |
| Abdel-Gaber, SA | 1 |
| Rahman, SAAE | 1 |
| Hafez, SMNA | 1 |
| Khalaf, HM | 1 |
| Safarpour, S | 3 |
| Pirzadeh, M | 1 |
| Ebrahimpour, A | 2 |
| Shirafkan, F | 2 |
| Madani, F | 1 |
| Hosseini, M | 2 |
| Moghadamnia, AA | 3 |
| Kazemi, S | 3 |
| Punt, CJA | 2 |
| Kwakman, JJM | 2 |
| Mol, L | 1 |
| Vater, LB | 1 |
| Lefebvre, B | 1 |
| Turk, A | 1 |
| Clasen, SC | 1 |
| Mansoori, R | 2 |
| Golchoobian, R | 1 |
| Moghaddam, Z | 1 |
| Rostami, M | 1 |
| Zeraatchi, A | 1 |
| Abadi, H | 1 |
| Karamitanha, F | 1 |
| Amirmoghaddami, H | 1 |
| Barary, M | 1 |
| Hosseinzadeh, R | 1 |
| Liang, JJ | 1 |
| Sio, TT | 1 |
| Osterlund, P | 1 |
| Kinos, S | 1 |
| Pfeiffer, P | 1 |
| Salminen, T | 1 |
| Frödin, JE | 1 |
| Shah, CH | 1 |
| Sorbye, H | 1 |
| Ristamäki, R | 1 |
| Halonen, P | 1 |
| Soveri, LM | 1 |
| Heervä, E | 1 |
| Ålgars, A | 1 |
| Bärlund, M | 1 |
| Hagman, H | 1 |
| McDermott, R | 1 |
| O'Reilly, M | 1 |
| Röckert, R | 1 |
| Liposits, G | 1 |
| Kallio, R | 1 |
| Flygare, P | 1 |
| Teske, AJ | 1 |
| van Werkhoven, E | 2 |
| Glimelius, B | 1 |
| Boldig, K | 1 |
| Ganguly, A | 1 |
| Kadakia, M | 1 |
| Rohatgi, A | 1 |
| Li, D | 3 |
| Song, C | 3 |
| Zhang, J | 3 |
| Zhao, X | 3 |
| Gui, Y | 1 |
| Famurewa, AC | 1 |
| Olatunji, OJ | 1 |
| Kasi, A | 1 |
| Gaudel, P | 1 |
| Lekkala, M | 1 |
| Al-Rajabi, R | 1 |
| Saeed, A | 1 |
| Sun, W | 1 |
| Porter, C | 1 |
| Mishra, T | 1 |
| Shokr, M | 1 |
| Ahmed, A | 1 |
| Afonso, L | 1 |
| Kanduri, J | 2 |
| More, LA | 2 |
| Godishala, A | 2 |
| Asnani, A | 3 |
| Allison, JD | 1 |
| Tanavin, T | 1 |
| Yang, Y | 1 |
| Birnbaum, G | 1 |
| Khalid, U | 1 |
| Dyhl-Polk, A | 1 |
| Vaage-Nilsen, M | 1 |
| Schou, M | 2 |
| Vistisen, KK | 1 |
| Lund, CM | 1 |
| Kümler, T | 1 |
| Appel, JM | 1 |
| Nielsen, DL | 1 |
| Raber, I | 1 |
| Warack, S | 1 |
| Pribish, A | 1 |
| Abovich, A | 1 |
| Orbite, A | 1 |
| Dommaraju, S | 1 |
| Frazer, M | 1 |
| Peters, ML | 1 |
| Shiga, T | 1 |
| Hiraide, M | 1 |
| Desai, A | 1 |
| Mohammed, T | 1 |
| Patel, KN | 1 |
| Almnajam, M | 1 |
| Kim, AS | 1 |
| Muhammad, RN | 1 |
| Sallam, N | 1 |
| El-Abhar, HS | 1 |
| Wang, Z | 2 |
| Qin, W | 1 |
| Zhai, Z | 1 |
| Huang, L | 1 |
| Feng, J | 1 |
| Guo, X | 1 |
| Liu, K | 1 |
| Zhang, C | 1 |
| Lu, G | 1 |
| Dong, S | 1 |
| Lane, S | 1 |
| Teperikidis, E | 1 |
| Boulmpou, A | 1 |
| Charalampidis, P | 1 |
| Tsavousoglou, C | 1 |
| Giannakoulas, G | 1 |
| Papadopoulos, CE | 1 |
| Vassilikos, V | 1 |
| Katharotiya, K | 1 |
| Shinde, G | 1 |
| Katharotiya, D | 1 |
| Shelke, S | 1 |
| Patel, R | 1 |
| Kulkarni, D | 1 |
| Panzade, P | 1 |
| Shehata, S | 1 |
| Bayoumi, AMA | 1 |
| El-Tahawy, NFG | 1 |
| Abdelzaher, WY | 1 |
| Tryfonidis, K | 1 |
| Marreaud, S | 1 |
| Khaled, H | 1 |
| De Valk, B | 1 |
| Vermorken, J | 1 |
| Welnicka-Jaskiewicz, M | 1 |
| Aalders, K | 1 |
| Bartlett, JMS | 1 |
| Biganzoli, L | 1 |
| Bogaerts, J | 1 |
| Cameron, D | 1 |
| Kounis, NG | 1 |
| Koniari, I | 1 |
| Patsouras, N | 1 |
| Koutsogiannis, N | 1 |
| Velissaris, D | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Franck, C | 1 |
| Malfertheiner, P | 1 |
| Venerito, M | 1 |
| Parve, S | 1 |
| Aliakberova, GI | 1 |
| Gylmanov, AA | 1 |
| Abdulganieva, DI | 1 |
| Heck, SL | 1 |
| Gulati, G | 1 |
| Hoffmann, P | 1 |
| von Knobelsdorff-Brenkenhoff, F | 1 |
| Storås, TH | 1 |
| Ree, AH | 1 |
| Gravdehaug, B | 1 |
| Røsjø, H | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Schulz-Menger, J | 1 |
| Omland, T | 1 |
| Cioffi, JH | 1 |
| Estes, DJ | 1 |
| Florou, V | 1 |
| Ardalan, B | 1 |
| Banke, A | 1 |
| Polk, A | 1 |
| Nielsen, D | 1 |
| Videbæk, L | 1 |
| Overgaard, U | 1 |
| Fosbøl, EL | 1 |
| Vaage-Nielsen, M | 1 |
| Nielsen, KM | 1 |
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Seker, M | 1 |
| Isen, HC | 1 |
| Çevirme, N | 1 |
| Aydın, S | 1 |
| Bilici, A | 1 |
| Bulut, H | 1 |
| Yasin, AI | 1 |
| Coban, E | 1 |
| Demir, T | 1 |
| Aliyev, A | 1 |
| Kocyigit, A | 1 |
| Turk, HM | 1 |
| Upshaw, JN | 1 |
| O'Neill, A | 1 |
| Carver, JR | 1 |
| Dimond, EP | 1 |
| Denlinger, CS | 1 |
| Kircher, SM | 1 |
| Wagner, LI | 1 |
| Ky, B | 1 |
| Brell, JM | 1 |
| Chakrabarti, S | 1 |
| Sara, J | 1 |
| Lobo, R | 1 |
| Eiring, R | 1 |
| Finnes, H | 1 |
| Mitchell, J | 1 |
| Hartgers, M | 1 |
| Okano, A | 1 |
| Halfdanarson, T | 1 |
| Grothey, A | 1 |
| Khan, K | 1 |
| Rane, JK | 1 |
| Cunningham, D | 1 |
| Rao, S | 1 |
| Watkins, D | 1 |
| Starling, N | 2 |
| Kalaitzaki, E | 1 |
| Forster, M | 1 |
| Braconi, C | 1 |
| Valeri, N | 1 |
| Gerlinger, M | 1 |
| Chau, I | 1 |
| Abdel-Rahman, O | 1 |
| Peng, T | 1 |
| Ouyang, Y | 1 |
| Tong, K | 1 |
| Hayashi, Y | 1 |
| Iijima, H | 1 |
| Isohashi, F | 1 |
| Tsujii, Y | 1 |
| Fujinaga, T | 1 |
| Nagai, K | 1 |
| Yoshii, S | 1 |
| Sakatani, A | 1 |
| Hiyama, S | 1 |
| Shinzaki, S | 1 |
| Makino, T | 1 |
| Yamasaki, M | 1 |
| Ogawa, K | 1 |
| Doki, Y | 1 |
| Takehara, T | 1 |
| Jin, X | 1 |
| Bai, Y | 1 |
| Gao, L | 1 |
| Wu, S | 1 |
| Anggadiredja, K | 1 |
| Tjandrawinata, RR | 1 |
| Knott, K | 1 |
| Rasheed, S | 1 |
| Foran, J | 1 |
| Cafferkey, C | 1 |
| Rosen, S | 1 |
| Nicholson, A | 1 |
| Baksi, J | 1 |
| Lyon, A | 1 |
| Rateesh, S | 1 |
| Shekar, K | 1 |
| Naidoo, R | 1 |
| Mittal, D | 1 |
| Bhaskar, B | 1 |
| Saneeymehri, SS | 1 |
| Markey, KR | 1 |
| Mahipal, A | 1 |
| Li, Y | 1 |
| Ju, L | 1 |
| Hou, Z | 1 |
| Deng, H | 1 |
| Zhang, Z | 1 |
| Wang, L | 1 |
| Yang, Z | 1 |
| Yin, J | 1 |
| Zhang, Y | 1 |
| Iskandar, MZ | 1 |
| Quasem, W | 1 |
| El-Omar, M | 1 |
| Vargo, CA | 1 |
| Blazer, M | 1 |
| Reardon, J | 1 |
| Gulati, M | 1 |
| Bekaii-Saab, T | 1 |
| Turan, T | 1 |
| Agac, MT | 1 |
| Aykan, AÇ | 1 |
| Kul, S | 1 |
| Akyüz, AR | 1 |
| Gökdeniz, T | 1 |
| Gül, İ | 1 |
| Cengiz, E | 1 |
| Boyacı, F | 1 |
| Erkan, H | 1 |
| Akdemir, R | 1 |
| Celik, S | 1 |
| van Ramshorst, MS | 1 |
| Honkoop, AH | 1 |
| Dezentjé, VO | 1 |
| Oving, IM | 1 |
| Mandjes, IA | 1 |
| Kemper, I | 1 |
| Smorenburg, CH | 1 |
| Stouthard, JM | 1 |
| Linn, SC | 1 |
| Sonke, GS | 1 |
| Madeddu, C | 1 |
| Deidda, M | 1 |
| Piras, A | 1 |
| Cadeddu, C | 1 |
| Demurtas, L | 1 |
| Puzzoni, M | 1 |
| Piscopo, G | 1 |
| Scartozzi, M | 1 |
| Mercuro, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer[NCT00036868] | Phase 2 | 90 participants (Actual) | Interventional | 2002-02-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for fluorouracil and Cardiac Toxicity
| Article | Year |
|---|---|
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Incidence; Neop | 2022 |
Fluoropyrimidine-Associated Cardiotoxicity.
Topics: Antimetabolites, Antineoplastic; Cardiotoxicity; Fluorouracil; Global Health; Heart Diseases; Humans | 2019 |
Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature.
Topics: Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colonic Neoplasms; Disease Progression; Elec | 2020 |
Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascula | 2020 |
5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
Topics: Cardiotoxicity; Death, Sudden; Fluorouracil; Humans; Myocarditis; Prospective Studies | 2021 |
5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.
Topics: Antineoplastic Agents; Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Retrospective Studies | 2022 |
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Topics: Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Neoplasms; Risk Factors | 2021 |
Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiotoxicity; | 2017 |
[Management of cardiovascular complications secondary to medical treatment of cancer].
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiotoxicity; Echocardiography; Electrocardiogr | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cardiotoxicity; Chest Pain; Co | 2016 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorourac | 2016 |
4 trials available for fluorouracil and Cardiac Toxicity
| Article | Year |
|---|---|
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2017 |
Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bipheny | 2018 |
Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Artery; Cardiotoxicity; Electr | 2018 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineo | 2016 |
38 other studies available for fluorouracil and Cardiac Toxicity
| Article | Year |
|---|---|
An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Topics: Capecitabine; Cardiotoxicity; Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Risk Assess | 2021 |
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Decision | 2022 |
Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Bosenta | 2022 |
Protective Effect of Kaempferol and Its Nanoparticles on 5-Fluorouracil-Induced Cardiotoxicity in Rats.
Topics: Animals; Biomarkers; Cardiotoxicity; Fluorouracil; Kaempferols; Male; Nanoparticles; Rats; Rats, Wis | 2022 |
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr | 2022 |
Cardioprotective effect of silymarin nanoemulsion on 5-fluorouracil-induced cardiotoxicity in rats.
Topics: Animals; Antioxidants; Cardiotoxicity; Cyclooxygenase 2; Fluorouracil; Male; Oxidative Stress; Rats; | 2022 |
EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cardiotoxicity; Female; Fluorourac | 2022 |
The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats.
Topics: Animals; Antioxidants; Cardiotoxicity; Cyclooxygenase 2; Doxorubicin; Fluorouracil; Male; Myocardium | 2022 |
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cardiotoxicity; Female; Fluorouracil; Humans; Male; Mi | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxici | 2022 |
Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis.
Topics: Animals; Cardiotoxicity; Ferroptosis; Fluorouracil; Glutathione; Mice; Myocytes, Cardiac; Phospholip | 2023 |
Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis.
Topics: Animals; Cardiotoxicity; Ferroptosis; Fluorouracil; Glutathione; Mice; Myocytes, Cardiac; Phospholip | 2023 |
Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis.
Topics: Animals; Cardiotoxicity; Ferroptosis; Fluorouracil; Glutathione; Mice; Myocytes, Cardiac; Phospholip | 2023 |
Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis.
Topics: Animals; Cardiotoxicity; Ferroptosis; Fluorouracil; Glutathione; Mice; Myocytes, Cardiac; Phospholip | 2023 |
Naringin ameliorates 5-fluorouracil induced cardiotoxicity: An insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters.
Topics: Animals; Antioxidants; Cardiotoxicity; Caspase 3; Doxorubicin; Fluorouracil; NF-kappa B; Oxidative S | 2023 |
A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Topics: Antimetabolites; Cardiotoxicity; Fluorouracil; Gastrointestinal Neoplasms; Humans; Outpatients; Retr | 2023 |
Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cardiotoxicity; Conservative Treatment; Diagnosis, D | 2019 |
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardio | 2020 |
Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
Topics: Capecitabine; Cardiotoxicity; Case-Control Studies; Fluorouracil; Humans; Retrospective Studies | 2020 |
5-Fluorouracil Rechallenge After Cardiotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Col | 2020 |
Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin.
Topics: Animals; Antimetabolites, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Endothelin-1; Enzyme A | 2020 |
Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomechanical Phenomena; Cardiotoxicity; Colo | 2021 |
Development, evaluation and biodistribution of stealth liposomes of 5-fluorouracil for effective treatment of breast cancer.
Topics: Breast Neoplasms; Cardiotoxicity; Edetic Acid; Female; Fluorouracil; Humans; Liposomes; Palmitates; | 2022 |
The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity.
Topics: Antioxidants; Cardiotoxicity; Caspase 3; Fenofibrate; Fluorouracil; Glutathione; Humans; Interleukin | 2022 |
Coronary vasospasm associated with 5-fluorouracil chemotherapy: Cardiac toxicity or cardiac hypersensitivity?
Topics: Acute Coronary Syndrome; Cardiotoxicity; Coronary Vasospasm; Drug Hypersensitivity; Fluorouracil; Hu | 2017 |
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2017 |
Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Dose-Res | 2017 |
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase | 2019 |
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox | 2019 |
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardio | 2019 |
5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cardiotoxicity; Cardiovascular Diseases | 2019 |
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Combined Modal | 2019 |
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi | 2019 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Cardiovascular effects of Phaleria macrocarpa extracts combined with mainstay FAC regimen for breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleeding | 2015 |
A case of Takotsubo syndrome following 5-fluorouracil chemotherapy.
Topics: Cardiotoxicity; Electrocardiography; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle | 2014 |
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac | 2015 |
Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics.
Topics: Animals; Biomarkers; Cardiotoxicity; Doxorubicin; Fluorouracil; Heart; Isoproterenol; Male; Metabolo | 2015 |
5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection.
Topics: Adult; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Cardiotoxicity; Colonic Neoplasms; | 2015 |
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2016 |
Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity.
Topics: Aged; Biomarkers; Cardiotoxicity; Early Diagnosis; Echocardiography; Fatty Acid-Binding Proteins; Fe | 2017 |